The role of radiation, with or without chemotherapy, in the management of NSCLC

Anuradha Chakravarthy, David Johnson, Hak Choy

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The role of adjuvant therapy remains to be clearly defined. Locally advanced non-small-cell lung cancer is too extensive for surgical resection, yet does not show evidence of metastatic disease. Historically, these patients were treated with radiation alone. More recent studies have provided the rationale for combining radiation with chemotherapy for patients with good performance status who have locally advanced disease. For patients with marginally resectable tumors, treatment is often given preoperatively (neoadjuvant) as a means of shrinking the tumor to make it resectable. In patients with clearly unresectable disease, radiation with chemotherapy has been established as better than either modality alone. Palliative radiation alone can be used for patients who cannot tolerate this aggressive approach. The optimal sequencing, as well as the best chemotherapeutic agent to use, remains under investigation. Some of the newer agents showing promise in the treatment of non-small-cell lung cancer include paclitaxel (Taxol) and carboplatin (Paraplatin). Other agents that. are currently under investigation include topotecan, gemcitabine, and vinorelbine (Navelbine).

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalOncology
Volume13
Issue number10 SUPPL. 5
StatePublished - 1999

Fingerprint

Radiation
Drug Therapy
Carboplatin
gemcitabine
Paclitaxel
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Topotecan
Neoplasms
Therapeutics
Cause of Death
Recurrence
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

The role of radiation, with or without chemotherapy, in the management of NSCLC. / Chakravarthy, Anuradha; Johnson, David; Choy, Hak.

In: Oncology, Vol. 13, No. 10 SUPPL. 5, 1999, p. 93-100.

Research output: Contribution to journalArticle

Chakravarthy, Anuradha ; Johnson, David ; Choy, Hak. / The role of radiation, with or without chemotherapy, in the management of NSCLC. In: Oncology. 1999 ; Vol. 13, No. 10 SUPPL. 5. pp. 93-100.
@article{f576a401304240f2b68c973c86db8d32,
title = "The role of radiation, with or without chemotherapy, in the management of NSCLC",
abstract = "Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The role of adjuvant therapy remains to be clearly defined. Locally advanced non-small-cell lung cancer is too extensive for surgical resection, yet does not show evidence of metastatic disease. Historically, these patients were treated with radiation alone. More recent studies have provided the rationale for combining radiation with chemotherapy for patients with good performance status who have locally advanced disease. For patients with marginally resectable tumors, treatment is often given preoperatively (neoadjuvant) as a means of shrinking the tumor to make it resectable. In patients with clearly unresectable disease, radiation with chemotherapy has been established as better than either modality alone. Palliative radiation alone can be used for patients who cannot tolerate this aggressive approach. The optimal sequencing, as well as the best chemotherapeutic agent to use, remains under investigation. Some of the newer agents showing promise in the treatment of non-small-cell lung cancer include paclitaxel (Taxol) and carboplatin (Paraplatin). Other agents that. are currently under investigation include topotecan, gemcitabine, and vinorelbine (Navelbine).",
author = "Anuradha Chakravarthy and David Johnson and Hak Choy",
year = "1999",
language = "English (US)",
volume = "13",
pages = "93--100",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 5",

}

TY - JOUR

T1 - The role of radiation, with or without chemotherapy, in the management of NSCLC

AU - Chakravarthy, Anuradha

AU - Johnson, David

AU - Choy, Hak

PY - 1999

Y1 - 1999

N2 - Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The role of adjuvant therapy remains to be clearly defined. Locally advanced non-small-cell lung cancer is too extensive for surgical resection, yet does not show evidence of metastatic disease. Historically, these patients were treated with radiation alone. More recent studies have provided the rationale for combining radiation with chemotherapy for patients with good performance status who have locally advanced disease. For patients with marginally resectable tumors, treatment is often given preoperatively (neoadjuvant) as a means of shrinking the tumor to make it resectable. In patients with clearly unresectable disease, radiation with chemotherapy has been established as better than either modality alone. Palliative radiation alone can be used for patients who cannot tolerate this aggressive approach. The optimal sequencing, as well as the best chemotherapeutic agent to use, remains under investigation. Some of the newer agents showing promise in the treatment of non-small-cell lung cancer include paclitaxel (Taxol) and carboplatin (Paraplatin). Other agents that. are currently under investigation include topotecan, gemcitabine, and vinorelbine (Navelbine).

AB - Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The role of adjuvant therapy remains to be clearly defined. Locally advanced non-small-cell lung cancer is too extensive for surgical resection, yet does not show evidence of metastatic disease. Historically, these patients were treated with radiation alone. More recent studies have provided the rationale for combining radiation with chemotherapy for patients with good performance status who have locally advanced disease. For patients with marginally resectable tumors, treatment is often given preoperatively (neoadjuvant) as a means of shrinking the tumor to make it resectable. In patients with clearly unresectable disease, radiation with chemotherapy has been established as better than either modality alone. Palliative radiation alone can be used for patients who cannot tolerate this aggressive approach. The optimal sequencing, as well as the best chemotherapeutic agent to use, remains under investigation. Some of the newer agents showing promise in the treatment of non-small-cell lung cancer include paclitaxel (Taxol) and carboplatin (Paraplatin). Other agents that. are currently under investigation include topotecan, gemcitabine, and vinorelbine (Navelbine).

UR - http://www.scopus.com/inward/record.url?scp=0033212177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033212177&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 93

EP - 100

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 5

ER -